• Our Approach
• Products in Development

The Novartis Oncology Pipeline:
A Broad Spectrum of Approaches

Developing agents targeting multiple pathways and tumor types

Novartis Oncology is currently developing a number of agents that block aberrant pathways in tumor cells, target tumor vasculature, or both. Through consistently delivering innovative therapies that reduce the burden of cancer, we will improve and extend the lives of cancer patients as we make therapies broadly available.

Search Novartis Oncology pipeline

Select your search criteria using 1 or more of the fields below.

All compounds are either investigational or studied in new indications. Efficacy and safety have not been established. There is no guarantee that they will become commercially available.

Learn more about clinical trials

• Download the Clinical Trial Seek app* and find clinical trials in your area
• View our educational e-brochure, “What is a cancer clinical trial?”
• Visit clinicaltrials.gov for more information about available trials

^*Available for iPhone^® and Android™ mobile devices.

iPhone is a registered trademark of Apple, Inc. Android is a trademark of Google, Inc.

This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis pipeline, readers should visit the Newsroom and Investors sections of our website.

This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results, performance, or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels. In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected.